Citius Pharmaceuticals, Inc. (CTXR)

$0.8941

-0.03 (-2.82%)
Rating:
Recommendation:
Neutral
Symbol CTXR
Price $0.8941
Beta 1.648
Volume Avg. 2.08M
Market Cap 130.655M
Shares () -
52 Week Range 0.831-2.47
1y Target Est -
DCF Unlevered CTXR DCF ->
DCF Levered CTXR LDCF ->
ROE -5918446.34% Strong Sell
ROA -5916982.91% Strong Sell
Operating Margin -
Debt / Equity 8.16% Neutral
P/E -
P/B 1.11 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest CTXR news


Mr. Myron Holubiak
Healthcare
Biotechnology
NASDAQ Capital Market

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.